Quantcast

Latest Bradmer Pharmaceuticals Inc. Stories

2009-07-17 06:00:00

TSX: BMR TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (TSX: BMR) ("Bradmer" or the "Corporation") announced today that its Board of Directors has authorized the Corporation to proceed with a substantial issuer bid (the "Offer"), pursuant to which the Corporation will offer to purchase for cancellation up to 8,300,000 million of its outstanding common shares ("Shares") at a price of Cdn$0.20 (approximately US$0.1788) per Share. The funds required to pay for Shares...

2009-05-07 06:00:00

TSX: BMR TORONTO, May 7 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") today announced its 2009 first quarter operational and financial results. Operational Highlights During the three months ended March 31, 2009, the Company commenced a strategic review of its operations, as more particularly described in news releases of the Company dated February 17, 2009, March 5, 2009, and March 31, 2009. Pursuant to the strategic review, the Company has closed its...

2009-03-31 15:30:00

TSX: BMR TORONTO, March 31 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results. Operational Highlights During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer: - Prepared and submitted...

2009-03-05 06:00:00

- Company suspends patient enrollment and contract manufacturing activities - TSX: BMR TORONTO, March 5 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), today announced that it will implement a restructuring plan to conserve existing cash resources. The plan is in response to the uncertain state of the capital markets and the Company's ongoing evaluation of strategic alternatives. As announced on February 17, 2009, a delay in completing the 60-patient "run-in...

2009-02-17 06:00:00

TSX: BMR TORONTO, Feb. 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), provided an update today on the ongoing Phase III GLASS-ART Trial testing Neuradiab(R) in the most advanced form of brain cancer (glioblastoma). Bradmer also announced that its Board of Directors has recommended a review of strategic options in light of performance, market conditions and new projections of site initiation and patient enrollment from the Company's clinical research organization (CRO)....

2008-12-09 09:11:00

TSX: BMR TORONTO, Dec. 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer will be presenting as a panel participant at the 2008 RBC Capital Markets Healthcare Conference, held at the Westin Times Square Hotel in New York City. The panel titled, Antibody Strategies For Fighting Cancer, is scheduled...

2008-12-01 07:00:00

TSX: BMR TORONTO, Dec. 1 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it has been granted European Patent, # 1351713, entitled "Anti-Tenascin Monoclonal Antibody Therapy For Lymphoma." The claims cover the use of the Company's lead product for Glioblastoma, 131-Iodine (131I) Neuradiab(TM) candidate (monoclonal antibody 81C6), which binds to tenascin for the...

2008-11-05 15:00:09

TORONTO, Nov. 5 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it is participating in a GBM (glioblastoma multiforme) Awareness Day as a co-host with Voices Against Brain Cancer. The event will take place on Wednesday, November 12, 2008, at the Four Seasons Hotel in New York City. The panel discussion will begin at 4:15pm ET. Dr. Alan M. Ezrin, President and...

2008-11-03 18:00:20

TORONTO, Nov. 3 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will present a corporate update at Rodman & Renshaw 10th Annual Healthcare Conference, which is being held in New York City from November 10th - 12th at the New York Palace Hotel. Dr. Ezrin will provide an update on the...

2008-09-30 09:00:18

TORONTO, Sept. 30 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced changes to its Board of Directors. Dr.ӚÓš EdӚÓš Miller, the Dean and Chief Executive Officer of Johns Hopkins University School of...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related